Hiteck(SZ:300683) Ge Long Hui A P P·2026-01-23 13:04Core Viewpoint - The company, Haitai Biological (300683.SZ), expects a significant loss in 2025, with projected losses ranging from 170 million to 240 million yuan, and a revenue forecast between 482.1 million and 586.59 million yuan [1] Group 1: Financial Performance - The company's raw materials and intermediates business is facing continuous losses due to intensified market competition and insufficient orders, leading to revenue falling short of expectations [1] - The subsidiary, Hanrui Pharmaceutical (Jingmen) Co., Ltd., has recognized an inventory impairment loss of approximately 11.93 million yuan due to declining sales prices influenced by market competition [1] - The subsidiary, Tianjin Hankan Pharmaceutical Biotechnology Co., Ltd., is expected to experience a decline in revenue due to market conditions and policy regulations, resulting in indications of goodwill impairment [1] Group 2: Impairment and Provisions - The company has made a cautious decision to recognize a goodwill impairment provision of 85 million yuan related to the acquisition of Tianjin Hankan's equity [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 28 million and 36 million yuan, primarily from investment income and government subsidies [1] - The equity method investment in Westway Pharmaceutical Technology (Shanghai) Co., Ltd. has resulted in a long-term equity investment impairment of 14.99 million yuan [1]